XML 43 R33.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenues (Details) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2020 USD ($) | Jun. 30, 2019 USD ($) | Jun. 30, 2020 USD ($) segment | Jun. 30, 2019 USD ($)
Revenue from Contract with Customer [Abstract] |  |  |  |
Number of operating segments | segment |  |  | 1 |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | $ 6,206 | $ 5,871 | $ 12,367 | $ 11,428
Product sales [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 5,908 | 5,574 | 11,802 | 10,860
Product sales [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 4,428 | 4,142 | 8,707 | 8,133
Product sales [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 1,480 | 1,432 | 3,095 | 2,727
Enbrel® (etanercept) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 1,246 | 1,363 | 2,399 | 2,514
Enbrel® (etanercept) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 1,213 | 1,315 | 2,330 | 2,421
Enbrel® (etanercept) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 33 | 48 | 69 | 93
Prolia® (denosumab) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 659 | 698 | 1,313 | 1,290
Prolia® (denosumab) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 441 | 458 | 863 | 848
Prolia® (denosumab) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 218 | 240 | 450 | 442
Neulasta® (pegfilgrastim) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 593 | 824 | 1,202 | 1,845
Neulasta® (pegfilgrastim) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 520 | 719 | 1,054 | 1,612
Neulasta® (pegfilgrastim) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 73 | 105 | 148 | 233
Otezla (apremilast) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 561 | 0 | 1,040 | 0
Otezla (apremilast) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 464 | 0 | 841 | 0
Otezla (apremilast) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 97 | 0 | 199 | 0
XGEVA® (denosumab) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 435 | 499 | 916 | 970
XGEVA® (denosumab) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 318 | 379 | 673 | 735
XGEVA® (denosumab) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 117 | 120 | 243 | 235
Aranesp® (darbepoetin alfa) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 387 | 436 | 809 | 850
Aranesp® (darbepoetin alfa) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 156 | 192 | 331 | 374
Aranesp® (darbepoetin alfa) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 231 | 244 | 478 | 476
KYPROLIS® (carfilzomib) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 253 | 267 | 533 | 512
KYPROLIS® (carfilzomib) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 167 | 166 | 354 | 320
KYPROLIS® (carfilzomib) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 86 | 101 | 179 | 192
Repatha (evolocumab) [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 200 | 152 | 429 | 293
Repatha (evolocumab) [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 115 | 91 | 239 | 174
Repatha (evolocumab) [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 85 | 61 | 190 | 119
Other products [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 1,574 | 1,335 | 3,161 | 2,586
Other products [Member] | US [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 1,034 | 822 | 2,022 | 1,649
Other products [Member] | ROW [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total product sales | 540 | 513 | 1,139 | 937
Other revenues [Member] |  |  |  |
Revenue from External Customer [Line Items] |  |  |  |
Total revenues | $ 298 | $ 297 | $ 565 | $ 568

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_EnbrelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_ProliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_NeulastaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_OtezlaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_XgevaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_AranespMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_KyprolisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_RepathaevolocumabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=amgn_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |